Panic disorder: Psychopathology, medical management and dental implications

Journal of the American Dental Association

Volumn 135, Issue 6, 2004, Pages 771-778

  Friedlander, Arthur H ^a,b,c   Marder, Stephen R ^a,d,e   Sung, Eric C ^b,f   Child, John S ^e,g,h  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UCLA MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UCLA SCHOOL OF DENTISTRY   (United States)

^g Ahmanson/UCLA Adult Congenital H   (United States)

^h Division of Cardiology

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTIBIOTIC AGENT; CITALOPRAM; CLONAZEPAM; DIAZEPAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; LORAZEPAM; PAROXETINE; SERTRALINE;

AGORAPHOBIA; BRUXISM; CLINICAL FEATURE; DENTAL CARIES; DENTISTRY; DEPRESSION; DYSGEUSIA; DYSPHAGIA; EDEMA; GINGIVITIS; GLOSSITIS; HUMAN; HYPERSALIVATION; MEDLINE; MITRAL VALVE PROLAPSE; PANIC; PATHOPHYSIOLOGY; PRESCRIPTION; PROPHYLAXIS; REVIEW; SIALOADENITIS; STOMATITIS; TONGUE DISEASE; TOOTH DISEASE; XEROSTOMIA;

EID: 3042515437     PISSN: 00028177     EISSN: None     Source Type: Journal    
DOI: 10.14219/jada.archive.2004.0306     Document Type: Article

References (63)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. Washington: American Psychiatric Association; 1994:394-403.
2. Glass RM. Panic disorder: it's real and it's treatable. JAMA 2000;283:2573-4.
3. Lesser IM, Rubin RT, Rifkin RP, et al. Secondary depression in panic disorder and agoraphobia, part II: dimensions of depression symptomatology and their response to treatment. J Affect Disord 1989;16(1):49-58.
4. Khan A, Leventhal RM, Khan S, Brown WA. Suicide risk in patients with anxiety disorders: a meta-analysis of the FDA database. J Affect Disord 2002;68(2-3):183-90.
5. Roy-Byrne PP, Stang P, Wittchen HU, Ustun B, Walters EE, Kessler RC. Lifetime panic-depression comorbidity in the National Comorbidity Survey: association with symptoms, impairment, course and help-seeking. Br J Psychiatry 2000;176:229-35.
6. Dammen T, Arnesen H, Ekeberg O, Husebye T, Friis S. Panic disorder in chest pain patients referred for cardiological outpatient investigation. J Intern Med 1999;245:497-507.
7. Weissman MM, Fyer AJ, Haghighi F, et al. Potential panic disorder syndrome: clinical and genetic linkage evidence. Am J Med Genet 2000;96(1):24-35.
8. Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial endocarditis: recommendations by the American Heart Association. JADA 1997;128:1142-51.
9. Masi G, Favilla L, Mucci M, Millepiedi S. Panic disorder in clinically referred children and adolescents. Child Psychiatry Hum Dev 2000;31(2):139-51.
10. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994;51(1):8-19.
11. Barzega G, Maina G, Venturello S, Bogetto F. Gender-related differences in the onset of panic disorder. Acta Psychiatr Scand 2001;103(3):189-95.
12. Yonkers KA, Zlotnick C, Allsworth J, Warshaw M, Shea T, Kellwe MB. Is the course of panic disorder the same in women and men? Am J Psychiatry 1998;155:596-602.
13. Katschnig H, Amering M, Stolk JM, Ballenger JC. Predictors of quality of life in a long-term followup study of panic disorder patients after a clinical drug trial. Psychopharmacol Bull 1996;32(1):149-55.
14. Roy-Byrne PP, Cowley DS. Course and outcome in panic disorder: a review of recent follow-up studies. Anxiety 1994-1995;1:151-60.
15. Kouzis AC, Eaton WW. Psychopathology and the initiation of disability payments. Psychiatr Serv 2000;51:908-13.
16. Gelernter J, Bonvicini K, Page G, et al. Linkage genome scan for loci predisposing to panic disorder or agoraphobia. Am J Med Genet 2001;105:548-57.
17. Crowe RR, Goedken R, Samuelson S, Wilson R, Nelson J, Noyes R Jr. Genomewide survey of panic disorder. Am J Genet 2001;105(1):105-9.
18. Hamilton SP, Fyer AJ, Durner M, et al. Further genetic evidence for a panic disorder syndrome mapping to chromosome 13 q. Proc Natl Acad Sci U S A 2003;100:2550-5.
19. Boshuisen ML, Ter Horst GJ, Paans AM, Reinders AA, den Boer JA. rCBF differences between panic disorder patients and control subjects during anticipatory anxiety and rest. Biol Psychiatry 2002;52(2):126-35.
20. Massana G, Gasto C, Junqué C, et al. Reduced levels of creatine in the right medial temporal lobe region of panic disorder patients detected with 1H magnetic resonance spectroscopy. Neuroimage 2002;16:836-42.
21. Austin DW, Richards JC. The catastrophic misinterpretation model of panic disorder. Behav Res Ther 2001;39:1277-91.
22. Klein DF. Panic disorder and agoraphobia: hypothesis hothouse. J Clin Psychiatry 1996;57(supplement 6):21-7.
23. Gorman JM, Kent JM, Sullivan GM, Coplan JD. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 2000;157:493-505.
24. Thomas KM, Drevets WC, Dahl RE, et al. Amygdala response to fearful faces in anxious and depressed children. Arch Gen Psychiatry 2001;58:1057-63.
25. Marshall RD, Blanco C, Printz D, Liebowitz MR, Klein DF, Coplan J. A pilot study of noradrenergic and HPA axis functioning in PTSD vs. panic disorder. Psychiatry Res 2002;110:219-30.
26. Practice guideline for the treatment of patients with panic disorder. Work Group on Panic Disorder. American Psychiatric Association. Am J Psychiatry 1998;155(supplement 5):1-34.
27. Bakker A, van Balkom AJ, Spinhoven P, Blaauw BM, van Dyck R. Follow-up on the treatment of panic disorder with or without agoraphobia: a quantitative review. J Nerv Ment Dis 1998;186:414-9.
28. Whittal ML, Otto MW, Hong JJ. Cognitive-behavior therapy for discontinuation of SSRI treatment of panic disorder: a case series. Behav Res Ther 2001;39:939-45.
29. Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder. JAMA 2000;283:2529-36.
30. Meredith LS, Sherbourne CD, Jackson CA, Camp P, Wells KB. Treatment typically provided for comorbid anxiety disorders. Arch Fam Med 1997;6(3):231-7.
31. Roy-Byrne PP, Stein MB, Russo J, et al. Panic disorder in the primary care setting: comorbidity, disability, service utilization, and treatment. J Clin Psychiatry 1999;60:492-9.
32. Bakker A, van Balkom AJ, Spinhoven P. SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr Scand 2002;106(3):163-7.
33. Kasper S, Resinger E. Panic disorder: the place of benzodiazepines and selective serotonin reuptake inhibitors. Eur Neuropsychopharmacol 2001;11:307-21.
34. Lydiard RB, Steiner M, Burnham D, Gegel I. Efficacy studies of paroxetine in panic disorder. Psychopharmacol Bull 1998;34(2):175-82.
35. Edwards JG, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 1999;57(4):507-33.
36. Spigset O. Adverse reactions to selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf 1999;20:277-87.
37. Goddard AW, Brouette T, Almai A, Jetty P, Woods SW, Charney D. Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 2001;58:681-6.
38. Nutt DJ. Neurobiological mechanisms in generalized anxiety disorder. J Clin Psychiatry 2001;62(supplement 11):22-7.
39. Physicians' desk reference. 57th ed. Montvale, N.J.: Thomson PDR; 2003.
40. McEvoy GK. AHFS drug information 2003. Bethesda, Md.: American Society of Health-System Pharmacists; 2003.
41. Zaubler TS, Katon W. Panic disorder and medical comorbidity: a review of the medical and psychiatric literature. Bull Menninger Clin 1996;60(2 supplement A):A12-38.
42. Gorman JM. A 28-year-old woman with panic disorder. JAMA 2001;286:450-7.
43. Martín-Santos R, Bulbena A, Porta M, Gago J, Molina L, Duro JC. Association between joint hypermobility syndrome and panic disorder. Am J Psychiatry 1998;155:1578-83.
44. Katerndahl DA. Panic and prolapse: meta-analysis. J Nerv Ment Dis 1993;181:539-44.
45. Flack JM, Kvasnicka JH, Gardin JM, Gidding SS, Manolio TA, Jacobs DR Jr. Anthropometric and physiologic correlates of mitral valve prolapse in a biethnic cohort of young adults: the CARDIA study. Am Heart J 1999;138:486-92.
46. Tamam L, Ozpoyraz N, San M, Bozkurt A. Association between idiopathic mitral valve prolapse and panic disorder. Croat Med J 2000;41:410-6.
47. Freed LA, Levy D, Levine RA, et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med 1999;341(1):1-7.
48. Perloff JK, Child JS. Mitral valve prolapse: evolution and refinement of diagnostic techniques. Circulation 1989;80:710-1.
49. Freed LA, Benjamin EJ, Levy D, et al. Mitral valve prolapse in the general population: the benign nature of echocardiographic features in the Framingham Heart Study. J Am Coll Cardiol 2002;40:1298-304.
50. Zwanzger P, Baghai T, Schule C, Rupprecht R. Treatment of mitral valve prolapse and panic disorder with metoprolol. World J Biol Psychiatry 2000;1(2):124-5.
51. Randall CW, Kressin NR, Garcia RI, Sims H, Kazis L, Jones JA. Heart murmurs: are older male dental patients aware of their existence? JADA 2001;132(2):171-6.
52. Sirois DA, Fatahzadeh M. Valvular heart disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;91(1):15-9.
53. Hamada T, Koshino Y, Misawa T, Isaki K, Gejyo F. Mitral valve prolapse and autonomic function in panic disorder. Acta Psychiatr Scand 1998;97(2):139-43.
54. St. John Sutton M, Weyman AE. Mitral valve prolapse prevalence and complications: an ongoing dialogue. Circulation 2002;106:1305-7.
55. Avierinos JF, Gersh BJ, Melton LJ 3rd, et al. Natural history of asymptomatic mitral valve prolapse in the community. Circulation 2002;106:1355-61.
56. Scully C, Roberts G, Shotts R. The mouth in heart disease. Practitioner 2001;245:432-7.
57. Carmona IT, Diz Dios P, Scully C. An update on the controversies in bacterial endocarditis of oral origin. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;93:660-70.
58. Pallasch TJ, Gage TW, Taubert KA. The 1997 prevention of bacterial endocarditis recommendations by the American Heart Association: questions and answers. J Calif Dent Assoc 1999;27:393-9.
59. Mask AG Jr. Medical management of the patient with cardiovascular disease. Periodontology 2000;23:136-41.
60. Callahan AM, Marangell LB, Ketter TA. Evaluating the clinical significance of drug interactions: a systematic approach. Harv Rev Psychiatry 1996;4(3):153-8.
61. Hersh EV. Adverse drug interactions in dental practice: interactions involving antibiotics - part II of a series. JADA 1999;130:236-51.
62. Ketter TA, Flockhart DA, Post RM, et al. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 1995;15:387-98.
63. Sansone RA, Sansone LA. Exacerbation of panic disorder symptoms following Vicodin exposure. Gen Hosp Psychiatry 2002;24:448-59.